Behind the Billion-Dollar Precision Medicine Market: Critical Challenges Remain Unresolved

In 2015, precision medicine (Precision Medicine) propelled gene sequencing into the spotlight; in 2016, spurred by overseas developments such as new drugs and IPOs, and catalyzed by favorable policies in China, precision medicine once again emerged as a powerful force.

From diagnosis to treatment, the application of precision medicine not only enhances healthcare efficiency and reduces adverse drug reactions but also significantly lowers medical costs. Consequently, precision medicine has garnered substantial attention from governments worldwide. Moreover, the tens of billions of dollars in opportunities embedded within the precision medicine sector have prompted an increasing number of international pharmaceutical giants and venture capital firms to compete for strategic positioning.

In an interview with a reporter, Liu Yu, Managing Director of the well-known venture capital firm Aoyin Capital, stated, “The future market size could reach trillions of yuan. Currently, China’s market scale is still below RMB 10 billion, yet the aggregate valuation of related companies has already approached RMB 100 billion. Nevertheless, for high-quality projects, we are willing to exercise greater tolerance.”

Recently, Celator Pharmaceuticals, a rising star in the U.S. precision medicine sector, created a wealth myth with its stock price soaring eightfold in just 18 days, sending shockwaves through the Nasdaq market. The A-share market, which has historically engaged in thematic speculation following major new trends in U.S. stocks, has also seen unusual activity in its precision medicine segment, with shares of Anke Biotechnology, Beilu Pharmaceutical, and Qianshan Medical Machine all rising. After several years of hype, do the related A-share sectors still offer further opportunities for profit? Behind this billion-dollar market, what critical issues remain to be addressed?

The market will reach $88 billion in 6 years

Precision medicine is a patient-specific healthcare model that leverages gene sequencing, proteomics, and the interdisciplinary application of bioinformatics and big data science to deliver treatments with greater precision than traditional approaches.

Traditional empirical medicine has led to the waste of medical resources and suboptimal therapeutic outcomes. According to statistics, the U.S. healthcare system wastes up to $750 billion annually on unnecessary and ineffective treatments, accounting for 30% of total healthcare expenditures. Dr. Zhaolong Gong, a renowned expert in new drug development and former senior new drug reviewer at the U.S. Food and Drug Administration (FDA), recently stated publicly at a pharmaceutical conference that, among oncology drugs, an average cancer drug is effective in only 25% of patients. Precision medicine can break this impasse by enabling personalized and precise medication—including drug selection and dosage—tailored to each individual’s condition. “This is the direction of future development.”

Precision medicine, grounded in individual genomic information, is a form of personalized healthcare based on biomolecular profiles that is tailored to each patient and disease. It aims to devise optimal treatment plans for patients, thereby maximizing therapeutic efficacy while minimizing adverse effects. Reporters have noted that although precision medicine is a relatively new development, this concept has, to varying degrees, existed within the healthcare sector for many years.

To gain deeper insights into opportunities in the precision medicine market, the reporter reviewed the “Global Precision Medicine Market (2015–2022) Report” released by the market research firm Research and Markets at the end of last year. The report states that the global precision medicine market is projected to reach $88 billion by 2022, with a compound annual growth rate (CAGR) of 12.6% from 2015 to 2022. North America and Europe are expected to lead the precision medicine market.

The report also points out that most breakthroughs in the precision medicine industry currently stem from advancements in cancer treatment technologies. In 2004, the probability of patients diagnosed with cancer receiving appropriate treatment was 10%, whereas this rate has now reached 70%–80%.

U.S. Precision Medicine to Focus on Cancer in the Short Term

The precision medicine market is gradually maturing, driven not only by the growing demand for personalized treatments and technological innovations and advances—including biomarker-based testing, next-generation gene sequencing, and precision imaging technologies—but also by significant government support.

In early 2015, the United States launched the Precision Medicine Initiative. According to details released on the White House’s official website, the U.S. fiscal budget for 2016 allocated a total of $215 million to agencies including the National Institutes of Health (NIH), the Food and Drug Administration (FDA), and the Office of the National Coordinator for Health Information Technology (ONC) to fund scientific research and innovative development in the field of precision medicine. Of this amount, $130 million was allocated to the NIH to support medical research involving a cohort of one million participants, aiming to enhance understanding of health and disease while laying the foundation for data-sharing mechanisms. Additionally, $70 million was allocated to the National Cancer Institute (NCI) for tumor genomics research and the development of more effective cancer treatments.

At this stage, the NIH is leveraging these funds to establish national-scale large research cohorts. Research data indicate that for every $1 invested in the Human Genome Project, the return amounts to $140.

According to the NIH website, the U.S. Precision Medicine Initiative has established short-term and long-term goals for different stages. In the short term, efforts will be concentrated on oncology, with the aim of expanding the application of precision medicine in cancer research. The National Cancer Institute (NCI) hopes to discover novel and more effective treatments for various types of cancer by continuously accumulating knowledge of the genetics and biology of diseases. The long-term goal is to extend precision medicine to large-scale public health and healthcare sectors. Currently, the role of precision medicine in routine healthcare remains relatively limited.

To this end, the NIH plans to launch a study involving at least one million volunteers across the United States. Participants will be required to provide their genetic data, biological samples, and other health information. These data will be utilized for large-scale disease research, with the ultimate goal of better predicting disease risk, understanding the etiologies of diseases, and identifying improved diagnostic and therapeutic strategies.

In overseas markets, in addition to the United States, both the United Kingdom and Australia have already established a presence in the precision medicine sector. UK Prime Minister David Cameron proposed the “100,000 Genomes Project” in 2012, which was officially launched in spring 2014 with the aim of completing whole-genome sequencing for 100,000 participants by 2017. Australia’s “100,000 Genomes Project” was also introduced in late 2015.

In the United States, the clinical application of precision medicine technologies is still in its early stages, with only a few companies achieving success. Myriad Genetics (NASDAQ: MYGN), a company focused on genetic testing for hereditary conditions in the U.S., generates hundreds of millions of dollars in annual revenue from its susceptibility gene testing products for BRCA1 and BRCA2 associated with breast cancer. Meanwhile, Editas Medicine, a gene-editing technology company that filed for an initial public offering (IPO) in January this year, has announced its ability to use gene-editing techniques to treat ophthalmic diseases, making it the first IPO company in the CRISPR gene-editing field.

A well-known venture capital firm, Aoyin Capital, told reporters that “genetic testing is the gateway to precision medicine.” Liu Yu revealed to reporters that they have reviewed numerous projects in the fields of precision medicine and genetic testing. “Our impression is that the sector is a mixed bag, with many startup projects proving less reliable than anticipated.”

“Rich Vein” Behind: A Host of Thorny Issues Await Resolution

At first glance, precision medicine appears to be a “gold mine” worth tens of billions of dollars, but at this stage, the industry still faces many practical challenges.

Reporters have learned that even in the United States, where the precision medicine industry is developing rapidly, many physicians currently lack the qualifications to perform DNA testing or are unable to accurately interpret test results for patients.

The New Yorker magazine published a real-life case. The interviewee was David Miller, a geneticist at Boston Children’s Hospital. At the time, a couple brought their five-year-old daughter to see him for medical evaluation. The girl was small in stature, appeared to have poor coordination, and was highly susceptible to external infections. Previous physicians had conducted DNA testing to determine whether her developmental delays were associated with any known genetic conditions. Based on the DNA test results, the physician concluded that the girl had a deletion in the 22q11 region of chromosome 22, indicating that she had DiGeorge syndrome. This syndrome is typically characterized by learning and growth delays, as well as congenital heart defects, and patients face an increased risk of developing psychiatric disorders later in life, such as schizophrenia. Currently, there is no known cure.

Upon receiving the test report, Miller conducted a thorough review and discovered that the location of the deletion on chromosome 22 did not correspond to the locus associated with DiGeorge syndrome. This finding suggested it was likely a benign genetic marker. Miller concluded that the short-statured girl did not actually have DiGeorge syndrome, a result that brought immense relief to her parents.

A review of relevant reports in U.S. media in recent years reveals that such misdiagnoses are relatively common, and the harm caused by these errors far exceeds merely inciting anxiety among patients or their parents. A 2012 study published in the journal Cancer described the case of a woman who underwent a hysterectomy—an extreme surgical intervention driven by a misinterpretation of genetic test results—thereby permanently losing her fertility.

Despite its rapid development, precision medicine remains a young and evolving field.

Currently, many of the technologies required to achieve the established goals of precision medicine are still in their early stages of development, or have not yet been discovered. For instance, when faced with over one million volunteers from hospitals and clinics across the United States, researchers need to identify standardized methods for data collection and effective solutions for storing vast amounts of patient information in databases.

The Precision Medicine Initiative has also raised ethical, social, and legal issues. Given the vast amount of health data involved, safeguarding the confidentiality of personal health information has become paramount. From the perspective of participant populations, it is essential to understand the benefits and risks of participating in research, which necessitates that researchers develop rigorous informed consent procedures.

Furthermore, cost is also a concern. The precision medicine initiative itself incurs costs in the millions of dollars, and as the project advances, it will require continuous financial support in the coming years. Technologies such as gene sequencing remain expensive at present (although sequencing costs are declining rapidly), and the development of drugs for targeted therapies based on genetic or molecular profiles is also costly. Third-party payers (such as private insurance companies) that bear the costs of these targeted therapies are also likely to face financial pressure.

If precision medicine evolves to become an integral part of routine healthcare in the future, physicians and other healthcare providers will need to possess a more profound foundation in molecular genetics and biochemistry. In this process, they will increasingly find themselves required not only to interpret genetic test results but also to understand how these findings inform subsequent therapeutic interventions or prior preventive measures, and to accurately convey this information to patients.

Sample of U.S. Listed Companies

Sample 1: Major Breakthrough in Testing New Leukemia Drug; Celator Surges Eightfold in 18 Days

Recently, an obscure small biopharmaceutical company in the United States has become a major star on the U.S. stock market after its share price surged more than eightfold over 18 trading days, attracting significant buying interest from major investors, including investment titan Steve Cohen.

Breakthrough Achieved in New Leukemia Drug

According to reporters, the company whose stock price has skyrocketed is Celator Pharmaceuticals Inc. (NASDAQ: CPXX), which was listed on the NASDAQ in October 2014. According to its official website, the company’s core business is the development and production of advanced biopharmaceutical products, as well as the research, development, and distribution of treatments for cancer, leukemia, and small cell lung cancer, with services covering the United States and Canada.

In mid-March, Celator suddenly announced significant positive news: its heavily promoted Vyxeos therapy demonstrated significantly greater efficacy than the standard of care currently used in late-stage clinical trials for extending survival in high-risk elderly patients with leukemia.

In a Phase III clinical study involving 309 patients with high-risk (secondary) acute myeloid leukemia (AML), those treated with Vyxeos, the novel leukemic drug CPX-351, achieved a median overall survival of 9.6 months from the start of the trial. In contrast, patients who received standard combination therapy with cytarabine and daunorubicin had a median overall survival of 6 months. Statistical data showed that two years into the trial, the survival rate in the Vyxeos group was approximately 31.1%, compared to 12.3% in the standard treatment group.

According to Celator Pharmaceuticals, the two trial groups exhibited comparable levels of adverse effects. In fact, while Vyxeos contains the same two drugs as the conventional standard-of-care regimen, it employs an innovative formulation and drug-delivery technology. In CPX-351, the two drugs are combined in a 5:1 ratio to optimize their respective concentrations in circulation.

In response to these encouraging trial results, the company stated that it would submit applications to the relevant authorities, aiming to secure official U.S. approval by the end of this year and obtain European approval in the first quarter of 2017. Following the news, Celator’s stock price surged.

Tech Titan Cohen Nets $20 Million in a Single Day

Celator’s new drug targets acute myeloid leukemia (AML), a rapidly progressing form of leukemia with incidence increasing with age. Among patients over 60, fewer than 10% survive five years.

On March 14, Celator Pharmaceuticals announced breakthrough progress for its new drug, leading to a mid-day trading halt. When trading resumed the following day, the stock surged 386% at the open. In the final half-hour of trading that day, the share price climbed further, closing at $9.03 with an astonishing gain of 437%, making it the top performer on the NASDAQ. Notably, Celator’s stock price stood at just $1.68 before the trading halt on March 14. As of April 22, Celator’s market capitalization reached $572 million, representing a cumulative increase of 836.3% since the resumption of trading. In accordance with U.S. Securities and Exchange Commission (SEC) regulations regarding abnormal stock price movements, investors holding more than 5% of the company’s shares were required to disclose their positions after the market close on March 15. Prominent U.S. hedge fund manager Steve Cohen appeared on Celator’s shareholder list. Disclosure filings revealed that Cohen held an 8.3% stake in Celator, making him the largest institutional holder of the pharmaceutical company. All of these shares were purchased immediately after Celator announced the successful results of its new drug trials.

According to Business Insider, Cohen acquired approximately 2.8 million shares of Celator through his family-run asset management firm, Point72, at purchase prices ranging from $1.50 to $2.10 per share, netting over $20 million in profit on March 15 alone. Point72 currently manages assets worth approximately $11 billion.

Sample 2: Sequencing Giant Illumina Makes High-Profile Entry into Liquid Biopsy, with Follow-on Investments from Gates and Bezos

If Celator is a rising star in the field of precision medicine, then Illumina (NASDAQ: ILMN) in the genetic testing market is the undisputed industry leader. As of April 22, the company’s market capitalization reached $21.1 billion. By this measure, Illumina is currently one of the top 20 largest companies in the U.S. biopharmaceutical sector.

Wall Street’s Darling of the Gene Sequencing Industry

Illumina is dedicated to the development, manufacturing, and sales of integrated systems for large-scale analysis of genetic variations and biological functions, which present high technical barriers. Currently, it provides services to genomic research centers, pharmaceutical companies, academic institutions, and biotechnology firms in the markets for sequence identification, genotyping, and gene expression.

Illumina conducted its initial public offering of 6 million shares on the Nasdaq market in 2000, with an issue price of $16 per share. It subsequently carried out two secondary offerings in May 2006 and August 2008, at prices of $25.5 and $87.5 per share, respectively.

Benefiting from the promising outlook of the industry and the company’s sustained performance growth as a market leader, Illumina has become a highly sought-after investment target on Wall Street, with its current share price reaching $136.

A check of the Bloomberg Terminal revealed that Illumina’s top five shareholders include several prominent institutional investors, such as BlackRock, the world’s largest private equity firm (6.76%), mutual fund giant The Vanguard Group (5.88%), and renowned investment bank Morgan Stanley (4.87%).

In fiscal year 2015, Illumina’s full-year revenue reached $2.22 billion, a year-over-year increase of 19%. Under Generally Accepted Accounting Principles (GAAP), net income attributable to shareholders of the parent company was $462 million. In fiscal year 2015, Illumina’s gross margin was 69.8%, slightly higher by 1 percentage point than that in fiscal year 2014. In 2015, the company’s research and development expenses increased to $402 million, compared with $388.1 million in 2014.

According to data from Illumina, the global market size for next-generation sequencing (NGS) applications is estimated at $20 billion, with oncology diagnostics and personalized medicine representing the most promising application areas, accounting for a market size of $12 billion.

Entering the Liquid Biopsy Field

In January of this year, Illumina, as the primary investor, established a new company named Grail, which conducts early cancer screening through simple blood tests. Jeff Huber, a senior Google executive, was subsequently recruited to serve as Grail’s Chief Executive Officer.

Grail’s focus on liquid biopsy is considered a potentially transformative approach to cancer detection. By screening for cancer through blood draws—capturing tumor cells or DNA shed into the bloodstream—it replaces the need to extract tissue directly from tumors, sparing some patients the pain of surgical and needle biopsies. This aligns with emerging trends in oncology diagnosis and treatment.

Reporters noted that this newcomer in the medical field has also attracted the favor of tech giants Bill Gates and Jeff Bezos (founder of Amazon), who both participated in the investment, bringing the total Series A funding to $100 million. If Gates and Bezos’ bets pay off, they stand to capture annual opportunities worth tens of billions, or even hundreds of billions, of dollars. Jay Flatley, an executive at Illumina, stated, “This (liquid biopsy) is a massive market, with an estimated value ranging from $20 billion to $200 billion.”

Grail plans to launch a product in 2019 that can detect multiple types of cancer at an early stage, priced under $1,000.

Despite the influx of top-tier venture capital and talent into this field, skepticism within the industry remains prevalent. For instance, “achieving precise early-stage blood screening will require a considerable amount of time; furthermore, even after technical benchmarks are met, it is essential to educate physicians and insurance companies about the benefits of such testing and successfully persuade them to adopt it.” More importantly, any flawed detection method could lead to misdiagnosis and inappropriate treatment, resulting in even more severe consequences.

Even the most ardent supporters of this technology have come to realize that their medical aspirations may not materialize. Richard Klausner, a board member at Grail, lamented, “Is making liquid biopsy an accepted testing standard worldwide an achievable dream or merely a pipe dream?” As a fledgling newcomer, Grail still needs to withstand the test of time.

From the perspective of stock price trends, Illumina’s share price has experienced significant volatility this year. Due to lower-than-expected sales of sequencing instruments such as the HiSeq 2500, 3000, and 4000, the company’s first-quarter revenue fell short of estimates. On April 19, Illumina’s stock price plunged dramatically by 23.16%, marking its largest single-day decline on record. However, investment bank analysts believe that Illumina’s performance downturn is an isolated case, largely driven by intensifying market competition, and that the overall outlook for the gene sequencing industry remains positive.

Source: National Business Daily